IPO Databook: Freenome (FRNM US) - Aug 2026

106 Views20 Aug 2026 10:03

SUMMARY

Freenome, Inc. is an early cancer detection company developing blood-based tests leveraging AI/ML to transform multi-cancer and multi-disease detection.
SimpleScreen CRC test received FDA approval as a blood-based screening option for CRC in adults 45 and older at average risk.
Proprietary technology platform with novel assay, scalable automation, and AI/ML expertise.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream